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Abstract
Survivin is a member of the inhibitor of apoptosis protein (IAP) family containing a single
baculovirus IAP repeat domain. It is expressed during fetal development but becomes undetectable
in terminally differentiated normal adult tissues. We previously reported that survivin and its
splicing variant survivin-2B was expressed abundantly in various types of tumor tissues as well as
tumor cell lines and was suitable as a target antigen for active-specific anti-cancer immunization.
Subsequently, we identified an HLA-A24-restricted antigenic peptide, survivin-2B80-88
(AYACNTSTL) recognized by CD8+ cytotoxic T lymphocytes (CTLs). We, therefore, started a
phase I clinical study assessing the efficacy of survivin-2B peptide vaccination in patients with
advanced or recurrent colorectal cancer expressing survivin. Vaccinations with survivin-2B peptide
were given subcutaneously six times at 14-day intervals. Of 15 patients who finished receiving the
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vaccination schedule, three suffered slight toxicities, including anemia (grade 2), general malaise
(grade 1), and fever (grade 1). No severe adverse events were observed in any patient. In 6 patients,
tumor marker levels (CEA and CA19-9) decreased transiently during the period of vaccination.
Slight reduction of the tumor volume was observed in one patient, which was considered a minor
responder. No changes were noted in three patients while the remaining eleven patients
experienced tumor progression. Analysis of peripheral blood lymphocytes of one patient using
HLA-A24/peptide tetramers revealed an increase in peptide-specific CTL frequency from 0.09% to
0.35% of CD8+ T cells after 4 vaccinations. This phase I clinical study indicates that survivin-2B
peptide-based vaccination is safe and should be further considered for potential immune and clinical
efficacy in HLA-A24-expression patients with colorectal cancer.
Background
Most patients who undergo operations for advanced
colorectal cancer remain at high risk for local or systemic
recurrence, and current chemotherapy or radiotherapy
regimens have limited efficacy in preventing recurrence.
Hence, advances in new therapeutic modalities for
patients with advanced or recurrent colorectal cancer are
urgently needed, one of which is tumor-specific
immunotherapy.
Tumor cells express antigens that can be recognized by the
host's immune system. T cells recognize antigens in the
form of short peptides binding to major histocompatibil-
ity complex (MHC) molecules [1]. Following the first
report of the cloning of a human tumor antigen gene,
termed melanoma antigen-1 (MAGE-1) in 1991 [2], a
nonapeptide encoded by this gene was identified that
could be recognized by HLA-A1-restricted CTLs [3]. To
date, a large number of antigenic peptides have been iden-
tified from melanoma and other cancers, and clinical tri-
als of peptide-based immunotherapy for cancer have
taken place. Melanoma antigen peptides were the first to
be tested in phase I and phase II studies for active immu-
nization of metastatic melanoma patients [2,4]. In some
studies, clinical responses have been observed in 10–30%
of the patients treated [5]. Rosenberg et al. reported that
clinical responses were observed in 42% of patients with
metastatic melanoma receiving a modified gp100 peptide
(gp100-209.2M) and systemic high dose of IL-2 [6]. Since
then, various cancer vaccine trials are ongoing in the
United States and Europe [5].
Survivin was identified as a member of the inhibitor of
apoptosis protein (IAP) family with a single baculovirus
IAP repeat domain [7]. Survivin is present during fetal
development but undetectable in terminally differenti-
ated normal adult tissues except for certain cells such as
proliferating endothelial cells and activated lymphocytes.
In contrast to normal tissues, survivin is abundantly
expressed in transformed cell lines and in most common
cancers, including colorectal cancer [8]. We previously
reported that survivin-2B, a splicing variant of survivin
was also expressed in various types of tumor cell lines9,
and the survivin-2B80-88 (AYACNTSTL) peptide derived
from exon 2B-encoded region was recognized by CD8+
CTLs in the context of HLA-A24 molecules [9]. CTLs spe-
cific for this peptide were successfully induced from
peripheral blood mononuclear cells (PBMCs) in 6 out of
7 HLA-A24+ patients (83%) with colorectal cancers and
exerted cytotoxicity against HLA-A24+ / survivin+ adeno-
carcinoma cells [10]. On the basis of these observations,
we have started a phase I clinical study of survivin-2B pep-
tide vaccination for patients with advanced or recurrent
colorectal cancer. Our present study demonstrated safety
and suggested marginal clinical effectiveness of the sur-
vivin-2B peptide vaccination in colorectal cancer patients.
Methods
Patient selection
The study protocol was approved by the Clinic Institu-
tional Ethical Review Board of the Medical Institute of
Bioregulation, Sapporo Medical University, Japan. All
patients gave informed consent before being enrolled.
Patients enrolled in this study were required to conform
to the following criteria: (1) to have histologically con-
firmed colorectal cancer, (2) to be HLA-A*2402 positive,
(3) to be survivin-positive in the carcinomatous lesions by
immunohistochemistry, (4) to be between 20 and 85
years old, (5) to have received surgical excision of the pri-
mary with curative intent and (6) to have ECOG perform-
ance status between 0 and 3. Exclusion criteria included
(1) prior cancer therapy, such as chemotherapy, radiation
therapy, steroid therapy, or other immunotherapy within
the past 4 weeks, (2) presence of other cancers that might
influence the prognosis, (3) immunodeficiency or a his-
tory of splenectomy, (4) severe cardiac insufficiency, acute
infection, or hematopoietic failure (5) ongoing breast-
feeding, (6) unsuitability for the trial based on clinical
judgment. This study was carried out at the Department of
Surgery, Sapporo Medical University Primary Hospital
from March 2003 through December 2003.Journal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/19
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Peptides preparation
The peptide, survivin-2B80-88 with the sequence AYAC-
NTSTL, was prepared under good manufacturing practice
conditions by Multiple Peptide Systems (San Diego, CA).
The identity of the peptide was confirmed by mass spec-
tral analysis, and the purity was shown to be more than
98% as assessed by high pressure liquid chromatography
analysis.
The peptide was supplied as a freeze-dried, sterile white
powder. It was dissolved in 1.0 ml of physiological saline
(Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan) and
stored at -80°C until just before use.
Patient treatment
The vaccination schedules were as follows. Vaccinations
with survivin-2B peptide were given subcutaneously (s.c.)
six times at 14-day intervals. In order to set up a dose-esca-
lation trial, the patients were separated into the following
three groups: group 1 patients received 0.1 mg, group 2
received 1.0 mg and group 3 received 10 mg. Each group
included five patients. Escalation to the next dose was
allowed if side effects did not exceed grade 3.
Delayed-type hypersensitivity (DTH) skin test
Delayed-type hypersensitivity (DTH) skin test was per-
formed at each vaccination. The peptide (10 µg) solution
in physiological saline (0.1 ml) or physiological saline
alone (0.1 ml) were separately injected intradermally
(i.d.) into the forearm opposite to the vaccination site. A
positive reaction was defined as a more than 4 mm diam-
eter area of erythema and induration 48 hr after the
injection.
Toxicity evaluation
Patients were examined closely for signs of toxicity during
and after vaccination. Adverse events were recorded using
the National Cancer Institute Common Toxicity Criteria
(NCI-CTC).
Clinical response evaluation
Physical examinations and hematological examinations
were monitored before and after each vaccination. Tumor
markers (CEA and CA19-9) were examined monthly.
Tumor size was evaluated by computed tomography (CT)
scans or MRI before treatment, after three vaccinations
and at the end of the study period. A complete response
(CR) was defined as complete disappearance of all meas-
urable and evaluable disease. A partial response (PR) was
defined as a >= 50% decrease from the baseline in size of
all measurable lesions (sum of products of maximal per-
pendicular diameters) lasting at least 4 weeks. Progressive
disease (PD) was defined as an increase in the sum of the
bi-dimensional measurements of all known disease sites
by at least 25% or the appearance of new lesions. No
change (NC) was defined as the absence of matched crite-
ria for CR, PR, or PD. In addition, one case that was
defined as NC but reached a nearly PR, was recorded as
minor response (MR). Therefore, a MR was defined as >
50% decrease from the baseline in all measurable lesions
(sum of products of maximal perpendicular diameters)
lasting less than 4 weeks or as a 25% to 50% decrease from
the baseline in all measurable lesions (sum of products of
maximal perpendicular diameters) lasting at least 4
weeks. Patients who received less than six vaccinations
were excluded from all evaluations in this study.
Tetramer staining
HLA-A24/peptide tetramers were constructed according to
the procedure described by Altman et al. [11]. Briefly,
recombinant HLA-A24 heavy chain [12] and human β-2-
microgloblin were refolded with survivin-2B80-88 pep-
tides as described before [13]. The resulting HLA-A24-
peptide monomer was biotinylated by incubation with
BirA enzyme (Avidity, Denver, CO) for 17 hr at room tem-
perature and purified using fast protein liquid chromatog-
raphy. Tetrameric HLA-peptide complex was produced by
incubating streptavidin-PE (Vector Laboratories, Burlin-
game, CA) with the biotinylated monomer at a 1:4 molar
ratio. For flow cytometric analysis, PBMCs were isolated
from blood samples by Ficoll-Conray density gradient
centrifugation, and stained with PE-labeled tetramer at
37°C for 20 min, followed by staining with FITC-conju-
gated anti-CD8 mAb (Beckton Dickinson Biosciences) at
4°C for 30 min. Cells were washed twice with PBS before
fixation in 1% formaldehyde. Flow cytometric analysis
was performed using FACSCalibur and Cell Quest soft-
ware (BD Biosciences). The frequency of CTL precursors
was calculated as the number of tetramer-positive cells
over the number of CD8-positive cells.
ELISPOT assay
ELISPOT plates were coated sterilely overnight with IFN-γ
capture antibody (Beckton Dickinson Biosciences) at
4°C. The plates were washed once and blocked with AIM-
V medium containing 10% human serum for 2 hr at room
temperature. CD8-positive T cells separated from patients'
PBMCs (5 × 103 cells/well) were then added to each well
along with HLA-A24-transfected CIR cells (CIR-A24) (5 ×
104 cells/well), which had been pre-incubated with or
without survivin-2B80-88 peptides (10 µg/ml). After
incubation in a 5% CO2 humidified chamber at 37°C for
24 hours, the wells were washed vigorously five times
with PBS and incubated with biotinylated anti-human
IFN-γ antibody and horseradish peroxidase-conjugated
avidin. Spots were visualized and analyzed by KS ELISPOT
(Carl Zeiss, Germany).Journal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/19
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Results
Patient profiles
Seventeen patients were initially enrolled in the study
(Table 1), but two (case 4 and 15) discontinued halfway
through the protocol. One patient (case 4) had lung and
brain metastases from rectal cancer and was removed
from the study after 2 vaccinations since he required ster-
oid therapy to suppress cerebral edema resulting from
brain metastasis. Another patient (case 15) had lung
metastases, liver metastases and carcinomatosis from
colon cancer. He was removed from the study after 4 vac-
cinations because of exacerbated dyspnea resulting from
advanced pulmonary metastases. Neither of the treatment
interruptions were due to the adverse effects of the vacci-
nation. Fifteen patients received the complete regimen
including six vaccinations and were evaluated. They
included 9 men and 6 women, whose average age was 59
years (range, 42–72). In for 4 cases colon cancer was the
primary diagnosis and the remaining 11 cases resulted
from rectal cancer.
Safety
Peptide vaccination was well tolerated in all 15 patients.
Three patients (case 1, 6, and 12) had slight toxicity-asso-
ciated symptoms such as anemia (grade 2), general
malaise (grade 1) and fever (grade 1). Case 1 developed
anemia after the second vaccination. Case 6 and case 12
experienced general malaise and fever after each vaccina-
tion followed by spontaneous recovery within a few days.
No serious adverse events were observed during or after
vaccination.
Clinical response
Table 1 summarizes the clinical outcomes for the 15
patients. In 6 patients (case 1, case 3, case 5, case 6, case 7,
case 9) tumor marker levels (CEA and CA19-9) transiently
decreased or at least did not increase during vaccination
(Table 2). A minor response was observed in one patient
(case 1) who also demonstrated a decrease in CEA level.
Three patients (case 3, 11, 17) were considered NC and
the remaining 11 PD.
It was noted retrospectively that all six patients in whom
a decrease in tumor marker level was observed had
received some sort of adjuvant chemotherapy after resec-
tion of the primary tumor without additional chemother-
apy after recurrence (Fig. 1). The details are as follows:
case 1 has received a daily dose of 600 mg tegafur/uracil
(UFT) for eight months as oral adjuvant chemotherapy.
He stopped receiving the drug at his own request. Case 3
received tegafur/uracil (UFT) at a daily dose of 600 mg for
two years as oral adjuvant chemotherapy. He discontin-
ued the medicine due to severe nausea. Case 5 received 5-
FU at a daily dose of 200 mg for three years as oral adju-
vant chemotherapy. Case 6 received 2 courses of CPT-11
(40 mg/day on the day 1, 8 and 15) every 4 weeks as adju-
vant chemotherapy. Subsequently, the patient discontin-
ued the treatment because of an increase in tumor
markers and a recurrence in the pleural cavity. Case 7
received 2 courses of leucovorin (750 mg/day on the day
1, 8 and 15) and 5-FU (250 mg/day on the day 1, 8 and
15) every 4 weeks as adjuvant chemotherapy. The patient
discontinued the treatment due to toxic effects that
Table 1: Profiles of patients enrolled in this study and clinical responses to the vaccination
patient no. age sex dose of 
peptide (mg)
adverse 
events
tumor 
marker
evaluation of 
CT imagea)
DTH skin test
1 63 M 0.1 anemia decreased MR --
25 3M 0 . 1- - n o t  d e c r e a s e d P D- -
3 42 M 0.1 -- decreased NC --
45 4F0 . 1- -
5 65 M 0.1 -- decreased PD --
6 64 F 0.1 general malaise decreased PD +
7 48 F 1.0 -- decreased PD --
86 2F1 . 0- - n o t  d e c r e a s e d P D- -
9 64 M 1.0 -- decreased PD --
10 52 M 1.0 -- not decreased PD +
11 58 M 1.0 -- not decreased NC +
12 58 F 10.0 fever not decreased PD --
13 62 F 10.0 -- not decreased PD +
14 72 M 10.0 -- not decreased PD +
15 71 M 10.0 --
16 67 M 10.0 -- not decreased PD --
17 59 F 10.0 -- not decreased NC +
a) MR: minor response, NC: no change, PD: progressive diseaseJournal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/19
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included severe nausea, loss of appetite, and gastritis. Case
9 had been treated with CPT-11 (40 mg/day) once a week
and 5'-DFUR (800 mg/day) every day for a year as adju-
vant chemotherapy. After recurrence, all patients were
treated with peptide vaccination without additional
chemotherapy. Interestingly, the patients who showed no
decrease in tumor markers received additional chemo-
therapy after recurrence and prior to vaccination. It is pos-
sible that the additional chemotherapy might have
interfered with the vaccine.
Among four patients who were defined as NC or MR, two
(case 1 and case 3) experienced decreases in tumor mark-
ers while the other two (case 11 and case 17) did not. In
case 11, levels of CEA have stayed within the normal range
(0~5.9 ng/ml) until the 4th vaccination and increased
thereafter (Fig. 2A). while CA19-9 levels stayed within the
normal range (0~37 U/ml) throughout the study (Fig.
2B).
Case 1 was a 63-year-old man who had advanced rectal
cancer. He underwent low anterior resection, followed by
receiving tegafur/uracil (UFT) at a daily dose of 600 mg as
adjuvant chemotherapy for one year. At his own request,
administration of the drug was discontinued. Three
months later, he self referred himself with pygalgia. CT
scan imaging demonstrated one lung metastasis, a tumor
in the pelvis and a mass in the urinary bladder. Cystos-
copy revealed that the bladder lesion was related to pros-
tate hypertrophy while colonoscopy confirmed recurrent
tumor in the pelvic cavity. The primary rectal cancer was
confirmed by immunohistochemical staining to express
survivin and the vaccination was started in March 2003.
CEA and CA19-9 were 15.9 ng/ml and 152.4 U/ml respec-
tively before treatment. They decreased continuously until
the 5th vaccination, at which points CEA and CA19-9
reached lowest levels, 6.5 ng/ml and 64.2 U/ml, respec-
tively. After the 6th vaccination, however, they returned to
increase to 16.2 ng/ml and 128.9 U/ml, respectively (Fig.
3A and 3B). After the 4th vaccination, CT scan imaging
revealed 32% reduction in volume of the recurrent pelvic
tumor (Fig. 4A and 4B) while rectal bleeding disappeared
after the 2nd vaccination.
DTH skin test
DTH skin test was performed at each vaccination and
assessed 48 hr later. A positive reaction was defined as ery-
thema and induration of more than 4 mm diameter. In 6
out of 15 patients (40%), a positive DTH reaction was
observed at least once during the study.
Tetramer staining assay and ELISPOT assay
In order to examine if the survivin-2B peptide vaccine
could bring about a specific immune response in the
patients, we analyzed the peptide-specifc CTL frequency
by using HLA-A24/peptide tetramer. Survivin-2B peptide-
specific CTL frequencies in PBMCs remained at back-
ground levels (less than 0.1 %) in all cases except for case
17. In case 17, the frequency of tetramer-positive CTL was
increased from 0.09% to 0.35% after the 4th vaccination
(Fig. 5). ELISPOT assay of CD8-positive T cells separated
from the patients' PBMCs failed to show the peptide-spe-
cific IFN-γ response in any patients (data not shown).
Overall this study suggests that the vaccination approach
that we attempted may provide marginal if any immuno-
logical or clinical benefit. However, it is possible that fur-
ther studies that may include a more intense
immunization schedule, delivery in the presence of
adjuvant and/or the combination of immune stimulatory
cytokines may enhance the activity of survivin as an
immunogen against cancer.
Discussion
Recently, a large number of tumor antigens and epitopes
recognized by cytotoxic T lymphocytes (CTLs) have been
identified, and reports of clinical trials utilizing peptide
vaccination are increasing [2,14-16]. However, most clin-
ical trials were aimed at the treatment of advanced
melanoma, and there are few reports of clinical trials for
patients with solid gastrointestinal tract cancer. Therefore,
we attempted to identify tumor antigens that are
expressed in a wide variety of solid gastrointestinal tract
Table 2: CEA levels of 6 patients who showed temporary decrease during the vaccination
Patient Baseline level (weeks) *1 *2 Lowest level (weeks) *2 Percent reduction *3 Duration of the 
decrease in CEA
Case 1 15.9 ng/ml (0 week) 6.5 ng/ml (7 weeks) 59.1 % 12 weeks
Case 3 34.0 ng/ml (5 weeks) 30.4 ng/ml (9 weeks) 10.6% 6.5 weeks
Case 5 184.0 ng/ml (0 week) 159.2 ng/ml (2 weeks) 13.5 % 8 weeks
Case 6 19.5 ng/ml (8 weeks) 19.4 ng/ml (10 weeks) 0.5 % 2 weeks
Case 7 230.0 ng/ml (0 week) 150.2 ng/ml (2 weeks) 34.7 % 3.5 weeks
Case 9 78.3 ng/ml (0 week) 71.7 ng/ml (8 weeks) 8.4 % 11 weeks
*1 CEA level just before the decrease, *2 Period after the first vaccination, *3 (Baseline level – Lowest level) / Baseline level × 100 (%)Journal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/19
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cancers. We demonstrated that survivin was expressed in a
large proportion of colorectal and gastric cancer speci-
mens, and the survivin-2B-derived peptide could induce
CTL response in the context of HLA-A24 [9,10]. In addi-
tion, we showed an elevation in CTL precursor frequen-
cies in PBMCs of HLA-A24+ cancer patients by using HLA-
A24/survivin-2B peptide tetramer. On the basis of the
above studies, we started a phase I clinical study of sur-
vivin-2B peptide vaccine therapy for patients with
advanced or recurrent colorectal cancer in March 2003. In
many clinical trials, patients received the peptide in com-
bination with certain adjuvant, such as IFA and cytokines,
for the purpose of enhancing immune responses against
cancer. In this study, patients received the survivin-2B
Treatment history of six patients who experience decrease in tumor marker levels during immunization Figure 1
Treatment history of six patients who experience decrease in tumor marker levels during immunization. Case 1 has received 
tegafur/uracil (UFT) at a daily dose of 600 mg for eight months as oral adjuvant chemotherapy. Case 3 received tegafur/uracil 
(UFT) at a daily dose of 600 mg for two years as oral adjuvant chemotherapy. Case 5 received 5-FU at a daily dose of 200 mg 
for three years as oral adjuvant chemotherapy. Case 6 received 2 courses of CPT-11 (40 mg/day) every 4 weeks as adjuvant 
chemotherapy. Case 7 received 2 courses of leucovorin (750 mg/day) and 5-FU (250 mg/day) every 4 weeks as adjuvant chem-
otherapy. Case 9 was treated with CPT-11 (40 mg/day) weekly and 5'-DFUR (800 mg/day) for a year as adjuvant chemother-
apy. They all had recurrences after the above adjuvant chemotherapy and received peptide-based vaccination without 
additional chemotherapy.
Case 1
Case 3
Case 5
Case 6
Case 7
Case 9
tegafur/uracil
for 8 months
tegafur/uracil for  2  years
5-FU    for   3   years
tegafur/uracil
LV
CPT-11     5‘-DFUR
for 2 months
CPT-11
for 2 months
for 1 year
operation
Peptide vaccine therapy
5-FUJournal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/19
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peptide dissolved in physiological saline without any
adjuvant in order to strictly evaluate the clinical effect of
the peptide alone.
A dose-escalation trial was chosen to estimate a safe and
optimal dose. 0.1 mg, 1.0 mg, and 10.0 mg dosage groups,
each consisting of five patients, were set up. Of the
patients in the 0.1 mg dose group, mild side effects were
observed in two patients, such as general malaise (grade
1) and anemia (grade 2). None of the patients receiving
1.0 mg had any sign of toxicity, and one of the patients in
the 10.0 mg dose group had slight fever (grade 1). No
greater than grade 3 toxicity was observed. Thus, we con-
clude that the survivin-2B peptide vaccine is safe and can
be repeatedly injected into patients without serious side
effect. In addition, there was no correlation between tox-
icity grade and dosage within the range of 0.1 mg to 10
mg.
In terms of clinical response, levels of tumor markers were
temporarily decreased compared with pre-treatment in
four patients in the 0.1 mg dosage group and two patients
in the 1.0 mg dosage group. No patients in the 10.0 mg
dosage group experienced decrease in tumor markers. In
Changes in serum tumor marker levels during the study in case 11 (A: CEA, B: CA19-9) Figure 2
Changes in serum tumor marker levels during the study in case 11 (A: CEA, B: CA19-9). Levels of CEA stayed within the nor-
mal range (0~5.9 ng/ml) until the 4th vaccination, and increased thereafter (A). Levels of CA19-9 stayed within the normal 
range (0~37 U/ml) throughout the study (B). Arrows indicate the times of vaccination.
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addition, a minor response was observed in one patient
who received 0.1 mg. Thus, there appeared to be no corre-
lation between clinical outcome and vaccine dosage.
Positive DTH reaction was observed in 6 out of 15
patients (40%) at least once during the vaccination. A pre-
vious report suggested a positive correlation between DTH
and clinical responses [17]. In this study, however, neither
level of tumor marker or tumor size were associated with
positive DTH reaction, except for one case (case 6).
In this study, six patients (case 1, case 3, case 5, case 6, case
7, case 9) had temporary decreases in the level of tumor
markers. It was noted that they had a history of adjuvant
chemotherapy after operation, and no additional chemo-
therapy after recurrence while all the other patients
received various kinds of chemotherapy after recurrence,
prior to the vaccine treatment. Although our study con-
sisted of only a limited number of patients, these prelim-
inary data may suggest that peptide-based vaccines might
be more effective in patients not immune-suppressed by
recent chemotherapy.
Patient in case 17 had advanced rectal cancer and was
operated on for creating a stoma without resection of the
tumor. Though the levels of tumor markers continued to
increase during the study, HLA-A24/peptide tetramer
analysis of CD8+ T cells in PBMCs suggested a minor
increase in frequency of peptide-specific CTL after the 4th
vaccination (approximately four-fold). It is possible that
this the CTL response induced by the vaccine might not be
sufficient to induce clinical regression in a patient with
advanced or the tetramer-positive CTL might be sup-
pressed in their cytotoxic function. Though immunologi-
Changes in serum tumor marker levels during the study in case 1 (A: CEA, B: CA19-9) Figure 3
Changes in serum tumor marker levels during the study in case 1 (A: CEA, B: CA19-9). Levels of CEA and CA19-9 were 15.9 
ng/ml and 152.4 U/ml, respectively before vaccination. Levels decreased continuously until the 4th or 5th vaccination to 6.5 ng/
ml and 64.2 U/ml, respectively. However, they increased to 16.2 ng/ml and 128.9 U/ml respectively after 6th vaccination. 
Arrows indicate the times of vaccination.
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cal monitoring has been executed using tetramer assay in
the other cases, tetramer-positive CTL frequencies were
under the detection limits even after the 6th vaccination. It
is obvious that a sensitivity of the assay has to be increased
to detect the specific CTL in patients' PBMCs. In some
reports, patients' PBMCs were stimulated with peptides in
the presence of IL-2 in vitro for several days before tetramer
assay. In our present immune monitoring study, we exam-
ined the CTL frequencies without such in vitro expansion
since it was anticipated that such an approach might not
be representative of the naturally occurring immune
response against the peptide in vivo.
This phase I clinical study revealed that the administration
of the survivin-2B peptide is safe. It is obvious that supe-
rior clinical and immunological responses are necessary
for cancer immunotherapy. Though vaccination with sur-
vivin-2B peptide alone was not enough to elicit overt clin-
ical responses, it is possible that vaccination with peptide
in combination with adjuvants or cytokines may be able
to lead to higher immune responses both in the induction
phase and in the effector phase. On the basis of the infor-
mation obtained from this study, we have recently started
the second clinical study of survivin-2B peptide vaccine in
CT scan image of the pelvis of patient reported as case 1 (A: before vaccination, B: after the 4th vaccination) Figure 4
CT scan image of the pelvis of patient reported as case 1 (A: before vaccination, B: after the 4th vaccination). The CT scan 
image demonstrates a reduction of tumor volume in the pelvic cavity after the 4th vaccination compared with before vaccina-
tion (32% reduction). The tumor had spread to the gluteus maximus muscle before treatment (white arrow in Panel A), 
whereas it appears separated from the muscle (white arrow in Panel B) after vaccination. The asterisk (*) indicates prostate 
hypertrophy. The sharp-mark (#) indicates a recurrent tumor in the pelvic cavity.
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combination with various adjuvants such as IFA, GM-CSF,
IL-2 and IFN-α.
Abbreviations
CTL; cytotoxic T lymphocyte
IAP; inhibitor of the apoptosis proteins
TAAs; tumor-associated antigens
ECOG; Eastern Co-operative Oncology Group
DTH; delyed-type hypersensitivity
CR; complete response
PR; partial response
NC; no change
PD; progressive disease
MR; minor response
IFA; incomplete Freund's adjuvant
Tetramer analysis of PBMCs from case 17 Figure 5
Tetramer analysis of PBMCs from case 17. Lymphocytes were collected from peripheral blood of the patient reported as case 
17 before the 1st vaccination (A) and after the 4th vaccination (B), stained with FITC-labeled antiCD8 mAb and PE-labeled HLA-
A24/survivin 2B peptide tetramer, and analyzed by flow cytometry. The frequency of tetramer-positive CTL was increased 
from 0.09% to 0.35% of CD8+ T cells after the 4th vaccination.
Fig. 5B Fig. 5A
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